Diagnostic and Interventional Cardiology

The annual congress of the European Heart Rhythm Association (EHRA), a branch of the ESC, will be held April 3-5 at the Bella Center in Copenhagen, Denmark and online. Explore the scientific program.

News | ESC

EHRA 2022: Cutting Edge Science in Heart Rhythm Disorders

March 31, 2022 — The annual congress of the European Heart Rhythm Association (EHRA), a branch of the ESC, will be held ...

March 31, 2022

News | Coronavirus (COVID-19)

International Multi-center Study Confirms Stroke Risk in Younger Healthier COVID-19 Patients

April 1, 2022 – Over the course of the pandemic, a number of studies examined whether COVID-19 patients were at ...

March 31, 2022

News | Population Health

Living Near Green Areas Reduces the Risk of Suffering a Stroke by 16%

April 1, 2022 – The risk of suffering an ischemic stroke, the most common type of cerebrovascular event, is 16% less in ...

March 31, 2022

Sponsored Content

Feature | Nuclear Imaging

Cardiac PET/CT — A New Standard for Cardiac Imaging

Cardiac PET/CT represents a major advancement in cardiovascular diagnostics, offering significant clinical and ...

November 12, 2025

Investigators from Cedars-Sinai have created an artificial intelligence-enabled tool that may make it easier to predict if a person will have a heart attack.

News | CT Angiography (CTA)

Artificial Intelligence Tool May Help Predict Heart Attacks

March 31, 2022 – Investigators from Cedars-Sinai have created an artificial intelligence-enabled tool that may make it ...

March 31, 2022

DiA Imaging Analysis Ltd, a leading global provider of AI-powered ultrasound analysis software, announced today a multi-year agreement with Change Healthcare, a global industry-leading provider of enterprise imaging solutions.

News | Cardiovascular Ultrasound

DiA Imaging Analysis Teams up with Healthcare Technology Company to Expand its AI Offering for Echo-lab Cardiac Exams

March 31, 2022 – DiA Imaging Analysis Ltd, a leading global provider of AI-powered ultrasound analysis software ...

March 31, 2022

Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has successfully completed enrollment in its phase 2 study of istaroxime in early cardiogenic shock caused by heart failure.

News | Pharmaceuticals

Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock

March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions ...

March 31, 2022

Sponsored Content

Feature

Intuitive Imaging Workflow System Offers Improved Efficiency, Flexibility

SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...

June 17, 2025

Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the publication of results from the first-in-human clinical trial of Embrace Hydrogel Embolic System (HES) for the treatment of hypervascular tumors, in the Journal of Vascular and Interventional Radiology (JVIR).

News | Embolization devices

Instylla First-In-Human Clinical Trial Published Results Demonstrate Technical Success and Persistent Embolization Across All Patients

March 31, 2022 – Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral ...

March 31, 2022

Vivasure Medical, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the first patient was treated in a U.S. early feasibility study evaluating PerQseal+, the next generation of the company’s PerQseal device.

News | Structural Heart

Vivasure Medical Announces First Patient Treated in U.S. Early Feasibility Study Evaluating PerQseal+

March 31, 2022 – Vivasure Medical, a company pioneering novel fully absorbable technology for percutaneous vessel ...

March 31, 2022

One in 5 people worldwide have high Lipoprotein(a) – sometimes referred to as “L-P-little a” – an important genetic risk factor for premature heart disease and stroke.

News | Heart Failure

The Silent, Undetected Cause of Early Heart Disease

March 31, 2022 – One in 5 people worldwide have high Lipoprotein(a) – sometimes referred to as “L-P-little a” – an ...

March 31, 2022

Sponsored Content

ASCEND provides the tools that not only address the unique needs of each cardiovascular subspecialty and to care for patients from infancy into their golden years, they also innovates next-generation solutions and services that empower the provider community to truly transform their cardiovascular services

Feature | Information Technology

SPONSORED CONTENT: Unveiling the Future of Cardiovascular Workflow

Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...

March 21, 2024

University Hospitals Cleveland Medical Center

News | Population Health

Study Shows Link Between Socioeconomic Deprivation and Premature Cardiovascular Mortality

March 31, 2022 – People living in socially-deprived areas of the United States are more likely to die prematurely from ...

March 31, 2022

A study conducted at São Paulo State University (UNESP) in Brazil shows that even mild to moderate infection by SARS-CoV-2 can cause an imbalance in the cardiovascular system of young adults without pre-existing diseases.

News | Coronavirus (COVID-19)

Study: Even Mild or Moderate COVID-19 Can Affect the Cardiovascular System in Young Adults

March 31, 2022 – A study conducted at São Paulo State University (UNESP) in Brazil shows that even mild to moderate ...

March 31, 2022

Clinician-scientists in the Smidt Heart Institute at Cedars-Sinai developed a clinical algorithm that, for the first time, distinguishes between treatable sudden cardiac arrest and untreatable forms of the condition.

News | Sudden Cardiac Arrest

Cedars-Sinai Researchers Are the First to Distinguish Between Treatable and Untreatable Sudden Cardiac Arrest

March 30, 2022 — Clinician-scientists in the Smidt Heart Institute at Cedars-Sinai developed a clinical algorithm that ...

March 30, 2022

Sponsored Content

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability to diagnose cardiac disease with greater accuracy and precision

Feature | Cardiac Imaging

SPONSORED CONTENT: Finding the Right Solution

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...

March 05, 2024

News | Computed Tomography (CT)

CCT Offers a Safer Alternative to Cardiac Catheterization in CAD Diagnosis

March 29, 2022 – Cardiac computed tomography (CCT) is an accurate, noninvasive diagnostic test for obstructive coronary ...

March 29, 2022

Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, has received US Food and Drug Administration (FDA) clearance for its Solus Gold Embolization Device, a next-generation product for peripheral vascular occlusion.

News | Embolization devices

Artio Medical Receives FDA Clearance for Solus Gold Embolization Device

March 29, 2022 – Artio Medical, Inc., a medical device company developing innovative products for the peripheral ...

March 29, 2022

Eko, a digital health company advancing heart and lung disease detection, has announced the launch of its newly-redesigned Eko App, which will transform patient interactions into an opportunity to screen for cardiovascular disease.

News | Heart Failure

Eko Launches Screening Solution to Help Catch Heart Disease Early

March 29, 2022 – Eko, a digital health company advancing heart and lung disease detection, has announced the launch of ...

March 29, 2022